(–)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells

References

• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010–4022
   PubMed Web of Science ®Google Scholar
• Savage D G, Antman K H. Imatinib mesylate – a new oral targeted therapy. N Engl J Med 2002; 346: 683–693
   PubMed Web of Science ®Google Scholar
• Goldman J M, Marin D, Olavarria E, Apperley J F. Clinical decisions for chronic myelogenous leukemia in the imatinib era. Semin Hematol 2003; 40(2 Suppl 2)98–103
   PubMed Web of Science ®Google Scholar
• Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs 1989; 38: 333–341
   PubMed Web of Science ®Google Scholar
• Tuszynski G P, Cossu G. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res 1984; 44: 768–771
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003; 66: 93–103
   PubMed Web of Science ®Google Scholar
• Chang J S, Hsu Y L, Kuo P L, Chiang L C, Lin C C. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol 2004; 31: 716–722
   PubMed Web of Science ®Google Scholar
• Liu S, Kulp S K, Sugimoto Y, Jiang J, Chang H L, Dowd M K, et al. The (–)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res 2002; 22: 33–38
   PubMed Web of Science ®Google Scholar
• Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, et al. (–)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005; 4: 197–205
   PubMed Web of Science ®Google Scholar
• Hou D X, Uto T, Tong X, Takeshita T, Tanigawa S, Imamura I, et al. Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch Biochem Biophys 2004; 428: 179–187
   PubMed Web of Science ®Google Scholar
• Ergun M A, Konac E, Erbas D, Ekmekci A. Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells. Cell Biol Int 2004; 28: 237–242
   PubMed Web of Science ®Google Scholar
• Van Poznak C, Seidman A D, Reidenberg M M, Moasser M M, Sklarin N, Van Zee K, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 2001; 66: 239–248
   PubMed Web of Science ®Google Scholar
• Wang G, Nikolovska-Coleska Z, Yang C Y, Wang R, Tang G, Guo J, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139–6142
   PubMed Web of Science ®Google Scholar
• Qiu J, Levin L R, Buck J, Reidenberg M M. Different pathways of cell killing by gossypol enantiomers. Exp Biol Med (Maywood) 2002; 227: 398–401
   PubMed Web of Science ®Google Scholar
• Cho S G, Choi E J. Apoptotic signaling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol 2002; 35: 24–27
   PubMedGoogle Scholar
• Keeshan K, Mills K I, Cotter T G, McKenna S L. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001; 15: 1823–1833
   PubMed Web of Science ®Google Scholar
• Lahaye T, Riehm B, Berger U, Paschka P, Muller M C, Kreil S, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005; 103: 1659–1669
   PubMed Web of Science ®Google Scholar
• Tauchi T, Ohyashiki K. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res 2004; 28(Suppl 1)S39–S45
   PubMed Web of Science ®Google Scholar
• Shah N P, Nicoll J M, Nagar B, Gorre M E, Paquette R L, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125
   PubMed Web of Science ®Google Scholar
• Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66: 10959–10966
   PubMed Web of Science ®Google Scholar
• Hoover R R, Mahon F X, Melo J V, Daley G Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068–1071
   PubMed Web of Science ®Google Scholar
• Radujkovic A, Topaly J, Fruehauf S, Zeller W J. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. Anticancer Res 2006; 26: 2169–2177
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003; 101: 3236–3239
   PubMed Web of Science ®Google Scholar
• Tseng P H, Lin H P, Zhu J, Chen K F, Hade E M, Young D C, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005; 105: 4021–4027
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore S W, Shoemaker A R, Armstrong R C, Augeri D J, Belli B A, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681
   PubMed Web of Science ®Google Scholar
• Le Blanc M, Russo J, Kudelka A P, Smith J A. An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol Res 2002; 46: 551–555
   PubMed Web of Science ®Google Scholar
• Mohammad R M, Wang S, Aboukameel A, Chen B, Wu X, Chen J, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) (–)-gossypol against diffuse large cell lymphoma. Mol Cancer Ther 2005; 4: 13–21
   PubMed Web of Science ®Google Scholar
• Mow B M, Chandra J, Svingen P A, Hallgren C G, Weisberg E, Kottke T J, et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002; 99: 664–671
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698
   PubMed Web of Science ®Google Scholar
• Aichberger K J, Mayerhofer M, Krauth M T, Skvara H, Florian S, Sonneck K, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303–3311
   PubMed Web of Science ®Google Scholar